18F-FDG PET/CT双时相显像对胰腺良恶性病变鉴别的诊断价值
Dual-Phase 18F-FDG PET/CT in the diagnosis of benign and malignant pancreatic lesions

DOI: 10.6040/j.issn.1671-7554.0.2015.1011

Keywords: 胰腺癌,PET/CT,¹⁸F-FDG,双时相,标准摄取值,
Pancreatic cancer,¹⁸F-FDG,Dual-Phase,Standardized uptake value,PET/CT

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Yoshioka M, Uchinami H, Watanabe G, et al. F-18 fluorodeoxyglucose positron emission tomography for differential diagnosis of pancreatic tumors[J]. Springerplus, 2015, 4: 154.
[2]	Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis[J]. J Comput Assist Tomogr, 2005, 29(4): 438-445.
[3]	Nakamoto Y, Higashi T, Sakahara H, et al. Delayed(<sup>18</sup>)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas[J]. Cancer, 2000, 89(12): 2547-2554.
[4]	Ozaki Y, Oguchi K, Hamano H, et al. Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography[J]. Gastroenterol, 2008, 43(2): 144-151.
[5]	Wang XL, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer[J]. World J Gastroenterol, 2014, 20(42): 15580-15589.
[6]	Tang S, Huang G, Liu J, et al. Usefulness of <sup>18</sup>F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis[J]. European Journal of Radiology, 2011, 78(1): 142-150.
[7]	Kawada N, Uehara H, Hosoki T, et al. Usefulness of Dual-Phase <sup>18</sup>F-FDG PET/CT for Diagnosing Small Pancreatic Tumors[J]. Pancreas, 2015, 44(4): 655-659.
[8]	Rijkers AP, Valkema BR, Duivenvoorden HJ, et al. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: A meta-analysis[J]. Eur J Surg Oncol, 2014, 40(7): 794-804.
[9]	Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour[J]. Nucl Med Commun, 2005, 26(10): 895-901.
[10]	Kamisawa T, Takum K, Anjiki H, et al. FDG-PET/CT findings of autoimmune pancreatitis[J]. Hepatogastroenterology, 2010, 57(99-100): 447-450.
[11]	Shigekawa M, Yamao K, Sawaki A, et a1. Is <sup>18</sup>F-fluorodeoxyglueose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?[J]. J Hepatobiliary Pancreat Sci, 2010, 17(3): 269-274.
[12]	Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases[J]. Eur J Nucl Med, 1997, 24(6): 678-682.
[13]	von Forstner C, Egberts JH, Ammerpohl O, et al. Gene expression patterns and tumor uptake of <sup>18</sup>F-FDG, <sup>18</sup>F-FLT, and <sup>18</sup>F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer[J]. J Nucl Med, 2008, 49(8): 1362-1370.
[14]	Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[<sup>18</sup>F] -fluoro-2-deoxy-D-glucose positron emission tomograpgy[J]. Gut, 1995, 36(5): 771-777.
[15]	Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies[J]. Surg Oncol Clin N Am, 2010, 19(2): 235-254.
[16]	Lodge MA, Lucas JD, Marsden PK, et al. A PET study of <sup>18</sup>FDG uptake in soft tissue masses[J]. Eur J Nucl Med, 1999, 26(1): 22-30.

Full-Text